Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity

Apoptosis

Volumn 12, Issue 3, 2007, Pages 561-571

  VanOosten, Rebecca L ^a,b   Earel Jr , James K ^a   Griffith, Thomas S ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Adenovirus; Caspase 2; HDACi; PKCK2; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BUTYRIC ACID; CASEIN KINASE; CASPASE 2; CASPASE 8; HISTONE DEACETYLASE INHIBITOR; N (4 METHOXYPHENYLACETYL)DEHYDROALANINE; PROTEIN KINASE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DEATH; CELL KILLING; CELL STRAIN; CONTROLLED STUDY; DRUG INHIBITION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 2; CASPASE 8; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE THERAPY; HISTONE DEACETYLASES; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, VIRUS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

ADENOVIRIDAE;

EID: 33847302895     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-0009-9     Document Type: Article

References (60)

1. Tripathy SK, Black HB, Goldwasser E, Leiden JM (1996) Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 2:545-50
2. Timme TL, Hall SJ, Barrios R, Woo SL, Aguilar-Cordova E, Thompson TC (1998) Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice. Cancer Gene Ther 5:74-82
3. Baratin M, Ziol M, Romieu R, et al (2001) Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-gamma delivery is associated with macrophages recruitment and nitric oxide production. Cancer Gene Ther 8:193-202
4. Rosenfeld MA, Yoshimura K, Trapnell BC, et al (1992) In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-155
5. Akli S, Caillaud C, Vigne E et al (1993) Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet 3:224-228
6. Le Gal La Salle G, Robert JJ, Berrard S, et al (1993) An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259:988-990
7. Cordier L, Duffour MT, Sabourin JC et al (1995) Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther 2:16-21
8. Bergelson JM, Cunningham JA, Droguett G, et al (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323
9. Harrison GS, Glode LM (1997) Current challenges of gene therapy for prostate cancer. Oncology (Williston Park) 11:845-850, 56; discussion 56-58, 61
10. Hrouda D, Perry M, Dalgleish AG (1999) Gene therapy for prostate cancer. Semin Oncol 26:455-471
11. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT (2000) The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 60:5031-5036
12. Rauen KA, Sudilovsky D, Le JL, et al (2002) Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma:potential relevance to gene therapy. Cancer Res 62:3812-3818
13. Sachs MD, Ramamurthy M, Poel H, et al (2004) Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 11:477-486
14. Zhang XD, Gillespie SK, Borrow JM, Hersey P (2003) The histone deacetylase inhibitor suberic bishydroxamate:a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 66:1537-1545
15. Neuzil J, Swettenham E, Gellert N (2004) Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase:role of Bcl-xL down-regulation. Biochem Biophys Res Commun 314:186-191
16. Rosato RR, Almenara JA, Dai Y, Grant S (2003) Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2:1273-1284
17. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T (2004) Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23:6261-6271
18. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL (2000) Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 165:2886-2894
19. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690
20. Wiley SR, Schooley K, Smolak PJ, et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682
21. Gliniak B, Le T (1999) Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59:6153-6158
22. Walczak H, Miller RE, Ariail K, et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163
23. Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL (2000) A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 7:1034-1038
24. Martin SJ, Reutelingsperger CP, McGahon AJ, et al (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus:inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182:1545-1556
25. VanOosten RL, Moore JM, Karacay B, Griffith TS (2005) Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biology & Therapy 4:1104-1112
26. Tomko RP, Xu R, Philipson L (1997) HCAR and MCAR:the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 94:3352-3356
27. Richon VM, O'Brien JP (2002) Histone deacetylase inhibitors:a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 8:662-664
28. Hemminki A, Kanerva A, Liu B, et al (2003) Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 63:847-853
29. VanOosten RL, Moore JM, Ludwig AT, Griffith TS (2005) Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 11:542-552
30. Griffith TS, Broghammer EL (2001) Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 4:257-266
31. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, Sanlioglu S (2006) Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther 13:21-31
32. Hara I, Miyake H, Hara S, Arakawa S, Kamidono S (2000) Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity. Int J Oncol 17:1213-1218
33. Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK (2005) Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7:646-657
34. Roy S, Packman K, Jeffrey R, Tenniswood M (2005) Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12:482-491
35. Jin Z, Dicker DT, El-Deiry WS (2002) Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 1:82-89
36. Izeradjene K, Douglas L, Delaney A, Houghton JA (2004) Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res 10:6650-6660
37. Izeradjene K, Douglas L, Delaney A, Houghton JA (2005) Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene 24:2050-2058
38. Ravi R, Bedi A (2002) Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res 62:4180-4185
39. Wang G, Ahmad KA, Ahmed K (2006) Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells. Cancer Res 66:2242-2249
40. Shin S, Lee Y, Kim W, Ko H, Choi H, Kim K (2005) Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J 24:3532-3542
41. Ruzzene M, Penzo D, Pinna LA (2002) Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364:41-47
42. Ashkenazi A, Pai RC, Fong S, et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162
43. Denis LJ (2000) The role of active treatment in early prostate cancer. Radiother Oncol 57:251-258
44. Stone NN, Stock RG (2000) Prostate brachytherapy in patients with prostate volumes >/= 50 cm (3):dosimetic analysis of implant quality. Int J Radiat Oncol Biol Phys 46:1199-1204
45. Steiner MS, Gingrich JR (2000) Gene therapy for prostate cancer:where are we now? J Urol 164:1121-1136
46. Bai M, Harfe B, Freimuth P (1993) Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol 67:5198-5205
47. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993) Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73:309-319
48. Dmitriev I, Krasnykh V, Miller CR, et al (1998) An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72:9706-9713
49. Li Y, Pong RC, Bergelson JM et al (1999) Loss of adenoviral receptor expression in human bladder cancer cells:a potential impact on the efficacy of gene therapy. Cancer Res 59: 325-330
50. Miller CR, Buchsbaum DJ, Reynolds PN et al (1998) Differential susceptibility of primary and established human glioma cells to adenovirus infection:targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 58:5738-5748
51. Pong RC, Lai YJ, Chen H, et al (2003) Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res 63:8680-8686
52. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer:causes and therapies. Nat Rev Cancer 1:194-202
53. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241:126-133
54. Johnstone RW (2002) Histone-deacetylase inhibitors:novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299
55. Kischkel FC, Hellbardt S, Behrmann I, et al (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579-5588
56. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM (1995) FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81:505-512
57. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV (1993) A novel domain within the 55 kd TNF receptor signals cell death. Cell 74:845-853
58. Itoh N, Nagata S (1993) A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 268:10932-10937
59. Medema JP, Scaffidi C, Kischkel FC, et al (1997) FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 16:2794-2804
60. Eickhoff B, Germeroth L, Stahl C, et al (2000) Trichostatin A-mediated regulation of gene expression and protein kinase activities:reprogramming tumor cells for ribotoxic stress-induced apoptosis. Biol Chem 381:1127-1132